- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02160652
Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Research Question: Is laparoscopic ureteral re-implantation, for the treatment of malignant ureteral obstruction, associated with high patency rates, low complication rates, and a significant improvement in quality of life?
Study design: A single center single arm prospective study, assessing the outcome of ureteral re-implantation for malignant ureteral obstruction.
Study population: Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
Intervention: Laparoscopic ureteral re-implantation.
Study Time line: This will be a 1 year study. At initiation a baseline physical exam, blood test, and ultrasonography will be performed. Baseline quality of life questionnaires will be filled. After the operation, Follow-up visits will occur at 1, 3, 6 and 12 months after surgery. At each follow up visit a medical history and physical examination, blood tests and quality of life questionnaires will be performed. At 3, 6 and 12 months renal ultrasonography will be performed.
Primary Endpoint: Ureteral patency at 6 months following treatment - assessed by stable or improved hydronephrosis and estimated glomerular filtration rate (eGFR) according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Study impact: Current treatments for malignant ureteral obstruction with nephrostomy tubes negatively impact the patient's quality of life. The findings of the current study may support the use of laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction, if patency is preserved, and quality of life is improved, following the procedure.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Adult patient, older than 18 years of age.
- Patient with malignant ureteral obstruction diagnosed by creatinine elevation with evidence of ureteral obstruction on imaging.
- Patient is scheduled for ureteral reimplantation due to extrinsic malignant ureteral obstruction.
- American Society of Anesthesiologist score ≤3, enabling the patient to undergo surgery.
- Life expectancy of over 6 months ( see exclusion criteria for definition)
- WHO performance status 0-2
- The patient is willing and able to read, understand and sign the study specific informed consent form
Exclusion criteria:
- Patients who underwent urinary diversion other than percutaneous nephrostomy or retrograde ureteral stenting prior to the planned treatment.
- Patients unable to sign an informed consent for or unwilling to undergo so.
Life expectancy of less than 6 months, as defined according to the criteria by Ishioka et al. and predicted in the presence of:
- Low serum albumin before percutaneous nephrostomy/ retrograde ureteral stenting (3 gm/dl or less).
- Low grade hydronephrosis prior to percutaneous nephrostomy/ retrograde ureteral stenting placement (grade 1 or 2) as graded by the grading system of the Society for Fetal Urology
- Malignant ascites or malignant pleural effusion.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients
Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
|
Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ureteral patency - 6 months
Time Frame: 6 months following the operation
|
Ureteral patency at 6 months following the operation- assessed by stable or improved hydronephrosis and estimated GFR according to the CKD-EPI equation.
|
6 months following the operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ureteral patency - 12 months
Time Frame: 12 months following the operation
|
Ureteral patency at 12 months following the operation.
|
12 months following the operation
|
|
Post-operative complications
Time Frame: 1, 3, 6, and 12-months following the operation
|
Post-operative complications 1, 3, 6, and12-months following the operation
|
1, 3, 6, and 12-months following the operation
|
|
Quality of life
Time Frame: 1,3,6, and 12 months following the operation
|
Changes in quality of life at 1,3, 6 and 12 months following the operation. Quality of life will be evaluated using two questionnaires:
|
1,3,6, and 12 months following the operation
|
|
Re-intervention
Time Frame: 12 months following the operation
|
Re-interventions following the operation.
|
12 months following the operation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0185-14-RMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ureteral Obstruction
-
Asan Medical CenterUnknownMalignant Ureteral ObstructionKorea, Republic of
-
University of LorraineCompletedChild, Only | Ureter Obstruction | UreterohydronephrosisFrance
-
Indiana Kidney Stone InstituteCompleted
-
South Valley UniversityRecruiting
-
University of Wisconsin, MadisonCompletedUreteral ObstructionUnited States
-
Lawson Health Research InstituteSt. Joseph's Health Care London; General ElectricWithdrawnUreteral ObstructionCanada
-
Samsung Medical CenterTaewoong Medical Co., Ltd.UnknownUreteral ObstructionKorea, Republic of
-
University of AarhusAarhus University HospitalCompletedUreteral ObstructionDenmark
-
First Affiliated Hospital of Chongqing Medical...Not yet recruitingUreteral Obstruction | Microbiome | Metabolomics | Ureteral StrictureChina
Clinical Trials on Laparoscopic ureteral re-implantation.
-
University Hospital OstravaUniversity of Ostrava; Vitkovice Hospital, Ostrava, Czech RepublicCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedPelvic Organ Prolapse | Stress Urinary IncontinenceFrance
-
EndoStim Inc.TerminatedGastroesophageal Reflux | Reflux, Gastroesophageal | Gastroesophageal Reflux Disease (GERD) | Acid RefluxUnited States, Belgium, Netherlands, United Kingdom
-
Meshalkin Research Institute of Pathology of CirculationCompletedParoxysmal Atrial Fibrillation | Failed First Radiofrequency Ablation ProcedureRussian Federation